# Compare Thymosin Alpha-1, Thymulin and KPV — Lazarus Research Peptides

> A side-by-side comparison of three Immune & Thymic research peptides — Thymosin Alpha-1, Thymulin, and KPV — across peptide class, evidence base, administration studied, regulatory status, and key caution.

Where these three immune and thymic peptides converge, where they diverge, and how far the evidence behind each one actually reaches.

## The short version

This page lines up [Thymosin Alpha-1](/thymosin-alpha-1), [Thymulin](/thymulin), and [KPV](/kpv) on the dimensions that matter most: what kind of molecule each is, where it has been studied, how strong that evidence is, how it was given in studies, its regulatory standing, and its single biggest caution. The headline: Thymosin Alpha-1 has the broadest human clinical record of the three, approved in more than 35 countries — though the largest sepsis RCT was null. Thymulin is the thymus gland's own output hormone, with evidence almost entirely in animal and gene-therapy models. KPV has no human trials at all. None is an approved medicine in the United States, and none is presented here with a human dose.

## The comparison matrix

| Dimension | Thymosin Alpha-1 | Thymulin | KPV |
| --- | --- | --- | --- |
| Peptide class | 28-aa N-terminally acetylated thymic immunomodulatory peptide | 9-aa zinc-dependent thymic nonapeptide hormone | 3-aa melanocortin-derived anti-inflammatory tripeptide |
| Most-studied in | Sepsis, viral hepatitis, cancer adjuvancy, COVID-19 | T-lymphocyte differentiation, neuroendocrine regulation, inflammatory lung | Gut inflammation (murine colitis) |
| Evidence base (model) | International clinical trials + human approved use [2]; largest sepsis RCT null [1] | Mostly animal and cell; gene-therapy models; no human trials of native thymulin [9][11] | In vitro + mouse only; no human trials [15] |
| Administration studied | Subcutaneous (clinical); IV pilot [1][2] | Intratracheal gene delivery, intracranial gene delivery, systemic in animals [8][11] | Oral / PepT1-targeted nanoparticle delivery in mice [13][14] |
| Regulatory / WADA status | Approved as thymalfasin in 35+ countries; not FDA-approved for US marketing | Not approved by FDA; research chemical only | Not approved; not specifically WADA-listed |
| Key caution | Largest sepsis RCT null (HR 0.99, P=0.93) [1]; US non-approval | Zinc-dependence entangles results; no human PK or dosing data [12] | Entirely preclinical; fragile tripeptide with no human PK [15] |

## Peptide class

The three span a wide size range. Thymosin Alpha-1 is the largest at 28 amino acids, a highly acidic thymic immunomodulatory polypeptide with an N-terminal acetyl cap that is essential for activity [7]. Thymulin is a 9-amino-acid peptide, but its effective form is actually the peptide-zinc complex: without zinc, the apopeptide is biologically silent [12]. KPV is the smallest at 3 amino acids, derived from a melanocortin hormone and carrying anti-inflammatory activity while dropping the parent hormone's pigmentary effect [17].

## Most-studied in

Each peptide has a research territory. Thymosin Alpha-1's clinical record covers sepsis, chronic hepatitis B and C, cancer immunotherapy adjuvancy, and COVID-19 lymphocyte restoration [2][3][4][5]. Thymulin's research centers on T-lymphocyte differentiation, the bidirectional thymus-neuroendocrine axis, and — in more recent work — anti-inflammatory gene therapy in inflammatory lung disease [8][11]. KPV is studied almost entirely in models of gut inflammation: chemically induced colitis in mice and the PepT1-dependent delivery mechanism that makes it selectively active in inflamed intestinal tissue [15][16].

## Evidence base (model)

The three are at genuinely different evidence stages. Thymosin Alpha-1 has the most human data — it has been through large multicentre RCTs including a phase-3 trial of 1,106 adults (null result) [1] and a previous smaller controlled trial (ETASS, marginal positive signal) [5], plus real-world use under regulatory approval in dozens of countries [2]. Thymulin sits in the preclinical middle ground: rigorous animal and cell evidence, promising gene-therapy demonstrations, but no completed human trial of the native nonapeptide [9][11]. KPV has the least human footing: the entire efficacy record is in vitro or murine colitis, with no human pharmacokinetics and no clinical trial [15].

## Administration studied

Routes reflect the research questions. Thymosin Alpha-1 is studied subcutaneously in clinical trials; the TESTS trial confirmed this route in 1,106 patients [1]. Thymulin's most striking recent evidence comes from intratracheal nanoparticle-delivered gene therapy in mice and from intracranial adenoviral delivery in rats — approaches designed to restore circulating or local thymulin where endogenous production is absent [8][11]. KPV's research is dominated by oral delivery in mice, typically via PepT1-targeted nanoparticle formulations designed to keep the labile tripeptide intact long enough to reach inflamed colon tissue [13][14].

## Regulatory / WADA status

Thymosin Alpha-1 (as thymalfasin) holds drug approval in more than 35 countries for hepatitis and immunodeficiency applications; it is not FDA-approved for marketing in the United States, where use is investigational or compounded [2]. Thymulin is not approved by any major regulator; it is handled as a research chemical for laboratory use only. KPV is similarly unapproved. Neither Thymulin nor KPV is specifically named on the WADA Prohibited List, but as unapproved peptides they should be treated cautiously in any sport or competitive context.

## Key caution

Each peptide carries a defining caveat. For Thymosin Alpha-1 it is the null large RCT: a phase-3 double-blind trial of 1,106 adults with sepsis found no significant mortality benefit, tempering earlier positive signals [1]. For Thymulin it is the zinc-dependence trap: activity is inseparable from zinc status, so any study's results are a compound of both thymulin and zinc availability, and there are no human pharmacokinetic data for the peptide itself [12]. For KPV it is the absence of any human evidence: a precisely mapped mechanism and a consistent murine signal, but no step yet into human trials [15]. The pattern across all three is the same: specific mechanisms, uneven evidence depth.

---

A literature digest of peer-reviewed immune and thymic peptide research — citations in hand, no products on offer.